scispace - formally typeset
M

Matteo Manica

Researcher at IBM

Publications -  64
Citations -  1486

Matteo Manica is an academic researcher from IBM. The author has contributed to research in topics: Computer science & Medicine. The author has an hindex of 12, co-authored 46 publications receiving 549 citations. Previous affiliations of Matteo Manica include ETH Zurich.

Papers
More filters
Journal ArticleDOI

BLOOM: A 176B-Parameter Open-Access Multilingual Language Model

Teven Le Scao, +386 more
- 09 Nov 2022 - 
TL;DR: BLOOM as discussed by the authors is a decoder-only Transformer language model that was trained on the ROOTS corpus, a dataset comprising hundreds of sources in 46 natural and 13 programming languages (59 in total).
Journal ArticleDOI

Mixed-precision in-memory computing

TL;DR: A hybrid system that combines a von Neumann machine with a computational memory unit can offer both the high precision of digital computing and the energy/areal efficiency of in-memory computing, which is illustrated by accurately solving a system of 5,000 equations using 998,752 phase-change memory devices.
Journal ArticleDOI

Mixed-Precision In-Memory Computing

TL;DR: In this article, a mixed precision in-memory computing (MIMO) system is proposed, which combines a von Neumann machine with a computational memory unit. But it does not address the limitations arising from device variability and nonideal device characteristics.
Journal ArticleDOI

Toward Explainable Anticancer Compound Sensitivity Prediction via Multimodal Attention-Based Convolutional Encoders.

TL;DR: In this article, a multimodal attention-based convolutional encoder was proposed for interpretable prediction of anticancer compound sensitivity using protein-protein interaction networks (PIPI).
Proceedings Article

CogMol: Target-Specific and Selective Drug Design for COVID-19 Using Deep Generative Models

TL;DR: A deep learning based generative modeling framework to design drug candidates specific to a given target protein sequence with high off-target selectivity is presented, and an in silico screening process that accounts for toxicity is augmented to lower the failure rate of the generated drug candidates in later stages of the drug development pipeline.